Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jul;183(1):201-7.
doi: 10.2214/ajr.183.1.1830201.

Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing success

Affiliations

Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing success

Ronald J Zagoria et al. AJR Am J Roentgenol. 2004 Jul.

Abstract

Objective: The objective of our study was to evaluate the success rate for radiofrequency ablation of renal tumors and to determine the risk of serious complications.

Conclusion: No serious complications occurred after 27 CT-guided radiofrequency ablation sessions in 22 patients. In total, no residual tumor was detected on follow-up contrast-enhanced CT or MRI 1-35 months (mean, 7 months) after final tumor ablation in 20 (91%) of 22 patients. Two patients with residual viable tumor deferred further treatment. Complete tumor ablation was achieved after a single treatment session in 83% of patients, and in 8% of patients after subsequent ablation sessions. Size was the major determinant for achieving tumor eradication with a single session of ablation, with all 11 tumors 3 cm or smaller being completely ablated after one session. Tumor location, histology, and the presence of renal disease did not correlate with treatment success. Contrast-enhanced CT performed immediately after ablation is reliable to exclude residual viable tumor. CT-guided radiofrequency ablation of renal tumors is safe and has a high rate of success in the treatment of small renal tumors, with no evidence of recurrence at midterm follow-up of treated patients.

PubMed Disclaimer

Comment in

LinkOut - more resources